tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

DE:NOTA Stock Latest News

FDA to begin requiring on clinical trial
The FlyFDA to begin requiring on clinical trial
5d ago
AZN
BMY
FDA to begin requiring one clinical trial in drug approvals
PremiumThe Fly
FDA to begin requiring one clinical trial in drug approvals
5d ago
AZN
BMY
Novartis announces Phase III RemIND trial met primary endpoint
PremiumThe Fly
Novartis announces Phase III RemIND trial met primary endpoint
5d ago
NVS
Novartis price target raised to $180 from $160 at TD Cowen
PremiumThe Fly
Novartis price target raised to $180 from $160 at TD Cowen
6d ago
NVS
Novartis: Vanrafia’s Mixed Phase III Data and Modest EPS Growth Support Balanced Risk‑Reward and Hold Rating
PremiumRatings
Novartis: Vanrafia’s Mixed Phase III Data and Modest EPS Growth Support Balanced Risk‑Reward and Hold Rating
6d ago
NVS
Novartis Vanrafia Phase III data supports slowing of kidney function decline
PremiumThe FlyNovartis Vanrafia Phase III data supports slowing of kidney function decline
10d ago
NVS
Novartis price target raised to CHF 135 from CHF 125 at JPMorgan
Premium
The Fly
Novartis price target raised to CHF 135 from CHF 125 at JPMorgan
11d ago
NVS
Novartis price target raised to EUR 135 from EUR 125 at Deutsche Bank
Premium
The Fly
Novartis price target raised to EUR 135 from EUR 125 at Deutsche Bank
11d ago
NVS
Sustained Growth Beyond Patent Cliffs: Confidence in Novartis’ Pipeline-Driven Upside to 2030
PremiumRatings
Sustained Growth Beyond Patent Cliffs: Confidence in Novartis’ Pipeline-Driven Upside to 2030
12d ago
NVS
Novartis’ treatment of progressive supranuclear palsy granted orphan designation
PremiumThe Fly
Novartis’ treatment of progressive supranuclear palsy granted orphan designation
13d ago
NVS
Novartis downgraded to Hold from Buy at DZ Bank
PremiumThe Fly
Novartis downgraded to Hold from Buy at DZ Bank
13d ago
NVS
Novartis breaks ground on biomedical research center in San Diego
PremiumThe Fly
Novartis breaks ground on biomedical research center in San Diego
17d ago
NVS
Trump Trade: Argentina says U.S. to cut hundreds of tariffs
PremiumThe FlyTrump Trade: Argentina says U.S. to cut hundreds of tariffs
17d ago
BA
AZN
Novartis Earnings Call: Record Margins Amid Generic Wave
Premium
Company Announcements
Novartis Earnings Call: Record Margins Amid Generic Wave
17d ago
NVS
Novartis price target lowered to CHF 132 from CHF 133 at Citi
Premium
The Fly
Novartis price target lowered to CHF 132 from CHF 133 at Citi
18d ago
NVS
TrumpRx website using technology from GoodRx, STAT says
PremiumThe Fly
TrumpRx website using technology from GoodRx, STAT says
18d ago
AZN
BMY
Novartis Faces Mounting ESG and Sustainability Risks That Could Weigh on Reputation, Financing, and Long-Term Value
PremiumCompany Announcements
Novartis Faces Mounting ESG and Sustainability Risks That Could Weigh on Reputation, Financing, and Long-Term Value
18d ago
NVS
Novartis: Resilient Core Performance and Medium-Term Pipeline Catalysts Support Buy Rating Despite Near-Term Guidance Softness
PremiumRatings
Novartis: Resilient Core Performance and Medium-Term Pipeline Catalysts Support Buy Rating Despite Near-Term Guidance Softness
19d ago
NVS
Buy Rating on Novartis: Near-Term Guidance Headwinds Outweighed by Resilient Fundamentals, Advancing Pipeline, and Supportive Valuation
PremiumRatings
Buy Rating on Novartis: Near-Term Guidance Headwinds Outweighed by Resilient Fundamentals, Advancing Pipeline, and Supportive Valuation
19d ago
NVS
Novartis: Resilient Core Earnings, Conservative Guidance and Robust Pipeline Support Buy Rating and EPS Upside to 2030
PremiumRatingsNovartis: Resilient Core Earnings, Conservative Guidance and Robust Pipeline Support Buy Rating and EPS Upside to 2030
19d ago
NVS
Novartis reports Q4 core EPS $2.03 vs. $1.98 last year
Premium
The Fly
Novartis reports Q4 core EPS $2.03 vs. $1.98 last year
19d ago
NVS
Novartis sees FY26 net sales up low single digits vs. last year
Premium
The Fly
Novartis sees FY26 net sales up low single digits vs. last year
19d ago
NVS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >